OncoMatch/Clinical Trials/NCT06952010
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Is NCT06952010 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including XB628 and Zanzalintinib for solid tumor.
Treatment: XB628 · Zanzalintinib — This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\[s\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic anticancer therapy — recurrent or metastatic
Cannot have received: nk cell-targeted therapy (monalizumab)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Exelixis Clinical Site #5 · San Francisco, California
- Exelixis Clinical Site #4 · New Haven, Connecticut
- Exelixis Clinical Site #8 · Tampa, Florida
- Exelixis Clinical Site #10 · Boston, Massachusetts
- Exelixis Clinical Site #11 · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06952010 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior nk cell-targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify